Use of Glucagon-Like-Peptide 1 Receptor Agonists and Risk of @entity174 as Compared to Use of Other Anti- XXXX Drugs.

@entity3604 @entity174 @entity6 @entity6757 @entity8142 @entity1602
UNASSIGNED: @entity8142 agonists ( @entity6757 RAs) are a new class of drugs that might have a potential beneficial effect on bone metabolism. Data on the effect of @entity6757 RAs and @entity174 risk are lacking. The aim of the present study was to investigate the association between the use of @entity6757 and the risk of @entity174 . A case-control study was performed using Danish National Health Service data. Cases were those who sustained a @entity174 and controls were those without a @entity174 during the study period (2007-2011), all aged 18  years and above. Conditional logistic regression estimated the odds ratios (OR) of @entity174 with current use of DPP4-I use. Analyses were adjusted for comorbidities and recent drug use. Among cases (n  =  229,114), there were 6993 current non-insulin anti- @entity6 drug (NIAD) users (excluding incretin users) and 255 @entity6757 RA users. Similarly, among controls (n  =  229,114), 7209 were NIAD users (excluding incretin users) and 220 were @entity6757 RA users. Current @entity6757 RA use was not associated with a decreased risk of @entity174 [adjusted (adj.) OR 1.16; 95  % CI 0.83-1.63]. @entity3604 risk was also not associated with current @entity6757 RA use (adj. OR 0.78; 95  % CI 0.44-1.39). In our nation-wide case-control study, we identified that the use of @entity6757 RA was not associated with @entity174 risk as compared to the use of other anti- @entity1602 drugs. Additionally, current @entity6757 RA use, stratified by cumulative or average daily dose, is not associated with @entity174 risk. Further research should focus on long-term use of @entity6757 RA and @entity174 risk.
